The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Objective To evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-
like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying …

This Consensus Report is intended to provide clinical professionals with evidencebased
guidance about individualizing nutrition therapy for adults with diabetes or prediabetes …

Background: Newer diabetes medications may have beneficial effects on mortality,
cardiovascular outcomes, and renal outcomes. Purpose: To evaluate the effectiveness …

Background Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce hospitalizations
and death from heart failure (HF), but their effect on arrhythmia expression has been poorly …

Background Cardiac arrhythmias are associated with poorer outcomes in patients with heart
failure (HF), diabetes mellitus (DM), and chronic kidney disease (CKD). Previous studies …

SGLT2 inhibitors are medications that have a unique mechanism of action and that lower
glucose independent of insulin. Given the recent findings on efficacy and benefits, these …

The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …

Aim The use of sodium glucose co‐transporter 2 (SGLT2) inhibitors in patients with type 2
diabetes mellitus (T2DM) and chronic kidney disease (CKD) has been limited, primarily …